Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $73.38 Average PT from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given a consensus rating of “Buy” by the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $73.38.

A number of brokerages have recently weighed in on JSPR. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. JMP Securities reiterated a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target on the stock. Evercore ISI reiterated an “outperform” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a report on Monday, August 26th. Finally, HC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, October 24th.

Jasper Therapeutics Trading Up 0.6 %

NASDAQ:JSPR opened at $20.60 on Friday. The business’s fifty day moving average price is $21.00 and its 200 day moving average price is $20.86. The firm has a market capitalization of $309 million, a price-to-earnings ratio of -4.35 and a beta of 2.18. Jasper Therapeutics has a 1-year low of $4.24 and a 1-year high of $31.01.

Institutional Trading of Jasper Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC increased its holdings in shares of Jasper Therapeutics by 320.7% during the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after acquiring an additional 12,308 shares during the last quarter. Jane Street Group LLC bought a new stake in Jasper Therapeutics during the third quarter worth approximately $251,000. Wellington Management Group LLP acquired a new position in Jasper Therapeutics during the third quarter valued at approximately $447,000. State Street Corp raised its position in shares of Jasper Therapeutics by 12.3% in the third quarter. State Street Corp now owns 214,883 shares of the company’s stock valued at $4,042,000 after purchasing an additional 23,564 shares during the period. Finally, Samsara BioCapital LLC lifted its stake in shares of Jasper Therapeutics by 11.4% in the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after buying an additional 59,642 shares during the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.